TheranosticTrials.org

Clinical Trial · NCT05543317

68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG

Overview

As a new dual receptor (integrin αvβ3 and FAP) targeting PET radiotracer, 68Ga-FAPI-RGD is promising as an excellent imaging agent applicable to various cancers. In this research, we investigate the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-RGD in healthy volunteers. Moreover, we evaluate the potential usefulness of 68Ga-FAPI-RGD positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, and compared with 18F-FDG PET/CT.

Sponsor

The First Affiliated Hospital of Xiamen University

Phase

N/A

Contacts

Long Sun, PhD (STUDY_CHAIR)

ClinicalTrials.gov

NCT05543317

Drug / Compound

FAPI-RGD

Isotope(s):
Target(s):
  • FAP
Ligand Class: Peptides
Chelator: DOTA

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report);
  • patients who had scheduled both 18F-FDG and 68Ga-FAPI-RGD PET/CT scans;

Exclusion

  • patients with non-malignant lesions;
  • patients with pregnancy;